Interaction between vascular factors and the APOE ε4 allele in predicting rate of progression in Alzheimer's disease
- PMID:21593560
- PMCID: PMC3164737
- DOI: 10.3233/JAD-2011-110086
Interaction between vascular factors and the APOE ε4 allele in predicting rate of progression in Alzheimer's disease
Abstract
Vascular factors have been shown to affect the rate of Alzheimer's disease (AD) progression. However, the effect of the APOE ε4 allele on rate of progression has been ambiguous. Little research to date has examined an interaction between vascular factors and the APOE ε4 allele in predicting decline among AD patients. 216 participants with incident AD from a population of elderly persons in Cache County, Utah, were followed for a mean of 3.3 years and 4.2 follow-up visits. A history of vascular risk factors and conditions and anti-hypertensive use was assessed at the diagnostic visit. Linear mixed effects models tested interactions between the vascular factors, APOE ε4, and time as predictors of clinical progression on the Mini-Mental State Exam (MMSE) and Clinical Dementia Rating-Sum of Boxes (CDR-SB). Multiple comparisons were corrected using the Holm-Bonferroni method. There was a 3-way interaction between stroke, APOE ε4 and time in predicting MMSE decline (LR χ² = 10.32, 2 df, p = 0.006). For the CDR-SB, there were 3-way interactions between the APOE ε4, time and either myocardial infarction (LR χ² = 17.83, 2 df, p = 0.0001) or stroke (LR χ² = 11.48, 2 df, p = 0.003. Results suggest a complex relationship between the APOE ε4 and vascular factors in predicting cognitive and functional progression. Among individuals with a history of stroke or myocardial infarction at baseline, progression of AD is influenced by APOE ε4 carrier status and varies by time after AD diagnosis.
Figures

Similar articles
- Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis.Elias-Sonnenschein LS, Viechtbauer W, Ramakers IH, Verhey FR, Visser PJ.Elias-Sonnenschein LS, et al.J Neurol Neurosurg Psychiatry. 2011 Oct;82(10):1149-56. doi: 10.1136/jnnp.2010.231555. Epub 2011 Apr 14.J Neurol Neurosurg Psychiatry. 2011.PMID:21493755
- Association ofAPOE Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease.Qian J, Betensky RA, Hyman BT, Serrano-Pozo A.Qian J, et al.Neurology. 2021 May 11;96(19):e2414-e2428. doi: 10.1212/WNL.0000000000011883. Epub 2021 Mar 26.Neurology. 2021.PMID:33771840Free PMC article.
- Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging.Hsiung GY, Sadovnick AD, Feldman H.Hsiung GY, et al.CMAJ. 2004 Oct 12;171(8):863-7. doi: 10.1503/cmaj.1031789.CMAJ. 2004.PMID:15477624Free PMC article.
- APOE ε4: the most prevalent yet understudied risk factor for Alzheimer's disease.Michaelson DM.Michaelson DM.Alzheimers Dement. 2014 Nov;10(6):861-8. doi: 10.1016/j.jalz.2014.06.015. Epub 2014 Sep 10.Alzheimers Dement. 2014.PMID:25217293Review.
- Apolipoprotein E (APOE) ε4 and episodic memory decline in Alzheimer's disease: A review.El Haj M, Antoine P, Amouyel P, Lambert JC, Pasquier F, Kapogiannis D.El Haj M, et al.Ageing Res Rev. 2016 May;27:15-22. doi: 10.1016/j.arr.2016.02.002. Epub 2016 Feb 11.Ageing Res Rev. 2016.PMID:26876367Free PMC article.Review.
Cited by
- Obesity as a risk factor for poor neurocognitive outcomes in older adults with heart failure.Alosco ML, Spitznagel MB, Gunstad J.Alosco ML, et al.Heart Fail Rev. 2014 May;19(3):403-11. doi: 10.1007/s10741-013-9399-2.Heart Fail Rev. 2014.PMID:23743688Free PMC article.Review.
- Reduced memory in fat mass and obesity-associated allele carriers among older adults with cardiovascular disease.Alosco ML, Benitez A, Gunstad J, Spitznagel MB, McCaffery JM, McGeary JE, Poppas A, Paul RH, Sweet LH, Cohen RA.Alosco ML, et al.Psychogeriatrics. 2013 Mar;13(1):35-40. doi: 10.1111/j.1479-8301.2012.00424.x.Psychogeriatrics. 2013.PMID:23551410Free PMC article.
- Combining modifiable risk factors and risk of dementia: a systematic review and meta-analysis.Peters R, Booth A, Rockwood K, Peters J, D'Este C, Anstey KJ.Peters R, et al.BMJ Open. 2019 Jan 25;9(1):e022846. doi: 10.1136/bmjopen-2018-022846.BMJ Open. 2019.PMID:30782689Free PMC article.
- Genome-wide association study of rate of cognitive decline in Alzheimer's disease patients identifies novel genes and pathways.Sherva R, Gross A, Mukherjee S, Koesterer R, Amouyel P, Bellenguez C, Dufouil C, Bennett DA, Chibnik L, Cruchaga C, Del-Aguila J, Farrer LA, Mayeux R, Munsie L, Winslow A, Newhouse S, Saykin AJ, Kauwe JSK; Alzheimer's Disease Genetics Consortium; Crane PK, Green RC.Sherva R, et al.Alzheimers Dement. 2020 Aug;16(8):1134-1145. doi: 10.1002/alz.12106. Epub 2020 Jun 23.Alzheimers Dement. 2020.PMID:32573913Free PMC article.
- Sex andAPOE ɛ4 modify the effect of cardiovascular risk on tau in cognitively normal older adults.Tsiknia AA, Reas E, Bangen KJ, Sundermann EE, McEvoy L, Brewer JB, Edland SD, Banks SJ; Alzheimer’s Disease Neuroimaging Initiative.Tsiknia AA, et al.Brain Commun. 2022 Feb 18;4(1):fcac035. doi: 10.1093/braincomms/fcac035. eCollection 2022.Brain Commun. 2022.PMID:35233525Free PMC article.
References
- Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261:921–923. - PubMed
- Bertram L, Tanzi RE. Thirty years of Alzheimer’s disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci. 2008;9:768–778. - PubMed
- Anand SS, Xie C, Pare G, Montpetit A, Rangarajan S, McQueen MJ, Cordell HJ, Keavney B, Yusuf S, Hudson TJ, Engert JC. Genetic variants associated with myocardial infarction risk factors in over 8000 individuals from five ethnic groups: The INTERHEART Genetics Study. Circ Cardiovasc Genet. 2009;2:16–25. - PubMed
- Elosua R, Ordovas JM, Cupples LA, Fox CS, Polak JF, Wolf PA, D’Agostino RA, Sr, O’Donnell CJ. Association of APOE genotype with carotid atherosclerosis in men and women: the Framingham Heart Study. J Lipid Res. 2004;45:1868–1875. - PubMed
Publication types
MeSH terms
Substances
Related information
Grants and funding
- K24-AG027841/AG/NIA NIH HHS/United States
- R01AG18712/AG/NIA NIH HHS/United States
- R01-HG005092/HG/NHGRI NIH HHS/United States
- R01 AG011380-12/AG/NIA NIH HHS/United States
- K24 AG027841/AG/NIA NIH HHS/United States
- R01 AG011380/AG/NIA NIH HHS/United States
- R01 AG018712/AG/NIA NIH HHS/United States
- R01AG21136/AG/NIA NIH HHS/United States
- R01 AG021136-07/AG/NIA NIH HHS/United States
- R01 HG005092-02/HG/NHGRI NIH HHS/United States
- R01 AG018712-03/AG/NIA NIH HHS/United States
- R01 HG002213/HG/NHGRI NIH HHS/United States
- R01AG11380/AG/NIA NIH HHS/United States
- R01 HG005092/HG/NHGRI NIH HHS/United States
- K24 AG027841-05/AG/NIA NIH HHS/United States
- R01-HG02213/HG/NHGRI NIH HHS/United States
- R01 HG002213-08/HG/NHGRI NIH HHS/United States
- R01 AG021136/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous